Zentalis Pharmaceuticals

$49.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (+0.16%) Today
$0.00 (0.00%) As of 9:16 PM UTC after-hours

Why Robinhood?

You can buy or sell ZNTL and other stocks, options, and ETFs commission-free!

About ZNTL

Zentalis Pharmaceuticals, Inc. Common Stock, also called Zentalis Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY. The listed name for ZNTL is Zentalis Pharmaceuticals, Inc. Common Stock.

CEO
Anthony Y. Sun
Employees
62
Headquarters
New York, New York
Founded
2014
Market Cap
2.05B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
332.93K
High Today
$50.70
Low Today
$47.34
Open Price
$49.93
Volume
210.90K
52 Week High
$61.29
52 Week Low
$22.00

Collections

ZNTL Earnings

-$2.88
-$1.92
-$0.96
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 8, Pre-Market

You May Also Like

SACH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure